Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.
Cureus · 2025
Last updated 2026-06-05| Journal | Cureus, 2025 |
|---|---|
| Citations | 1 |
| Molecules | tirzepatide |
Abstract
We present the case of a 52-year-old woman who developed a functional small bowel obstruction despite having no history of abdominal surgery, prior bowel obstruction, or GI interventions. The only notable recent change in her medical history was a dose escalation of Zepbound (tirzepatide), a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonist prescribed for weight loss. This case raises concern about potential severe GI motility complications associated with Zepbound, particularly in the absence of conventional SBO risk factors.
Verbatim abstract via PubMed 40978855 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.